Malvern Panalytical NanoSight Pro: Nanoparticle Tracking Analysis (NTA) instrument for accurately characterizing bio and nanoparticles

171.895,08 €

140.000 €

CERCA GINYS-III 004

Equipped with four interchangeable lasers (405 nm, 488 nm, 532 nm, and 642 nm), this system enables versatile and accurate detection of a wide range of nanoparticles, including extracellular vesicles, liposomes, viruses, metallic nanoparticles, and polymers. The ability to select the most appropriate laser based on the optical properties of the particles and the fluorophores used optimizes both scattered-light detection and fluorescence analysis. The system provides detailed information on concentration, size, distribution, and, in fluorescent mode, on labeled subpopulations, making it particularly useful for cell biology, nanomedicine, and drug development studies. Its automated design and intuitive interface, coupled with an automatic alignment and temperature control system, ensure reproducibility, ease of use, and high throughput. The ability to operate with multiple wavelengths makes it a suitable tool for multiparameter studies and for the specific detection of particle subtypes using fluorescent labeling. This significantly expands the analytical capabilities of the equipment, facilitating the development of more complex and specific experimental protocols in biomedical and nanotechnology research settings.

The versatility and cross-functional value of the NanoSight Pro make it a strategic resource for multiple scientific groups and platforms. Its acquisition will promote synergies not only with the research centers that supported the proposal but also with other external centers in fields other than biomedical research, facilitating multicenter projects and the sharing of cutting-edge technology. It will also strengthen existing collaborative networks and open up new opportunities for cooperation at the regional, national, and international levels by offering benchmark equipment that covers common needs in emerging fields such as extracellular vesicle biogenesis or the characterization of therapeutic nanoparticles.

The scientific advances made possible by the use of NanoSight Pro will have a direct impact on the development of biomedical solutions aimed at real clinical needs. The device's ability to accurately characterize extracellular vesicles, viruses, and other relevant nanoparticles in the pathophysiological context will allow for a deeper understanding of the molecular mechanisms involved in various diseases. This will facilitate the identification of new noninvasive biomarkers for early diagnosis, as well as the design of more effective and safe targeted therapies. The return to society will therefore result in a better response capacity of the healthcare system to challenges such as cancer, neurodegenerative, cardiovascular, and infectious diseases. In the medium and long term, the generation of applicable and transferable knowledge will contribute to more preventative, personalized, and efficient medicine, improving patients' quality of life and optimizing the use of public healthcare resources. Furthermore, the results derived from its use will strengthen the scientific production of the groups involved, increasing their competitiveness in national and international calls, and positioning biomedical research as a driver of innovation with a tangible impact on the well-being of the population.

The equipment will facilitate the development and characterization of products in preclinical or validation phases, such as nanomedicine formulations, drug delivery vehicles, or extracellular vesicle-based technologies such as biomarkers or therapeutic platforms. The improved analytical capacity will foster public-private collaborations with companies in the biotechnology, pharmaceutical, and diagnostics sectors, facilitating the valorization of results and the creation of patents, spin-offs, and collaborative R&D projects.

The NanoSight Pro will enable highly sensitive analysis of the concentration, size distribution, and subpopulations of nanoparticles such as extracellular vesicles, liposomes, viruses, functionalized nanoparticles, and protein complexes. Its ability to perform fluorescent analysis with different wavelengths will facilitate multiparametric and specific biomarker studies. This will enhance research lines in cancer, neurodegenerative diseases, infectious diseases, and personalized medicine, providing more robust, reproducible, and detailed data. It will also enable the development of new experimental protocols with standards comparable to those required by high-impact journals and regulatory agencies.